Journal of Scleroderma and Related Disorders

Scope & Guideline

Leading the way in scleroderma and related disorder advancements.

Introduction

Explore the comprehensive scope of Journal of Scleroderma and Related Disorders through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore Journal of Scleroderma and Related Disorders in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN2397-1983
PublisherSAGE PUBLICATIONS LTD
Support Open AccessNo
CountryItaly
TypeJournal
Convergefrom 2016 to 2024
AbbreviationJ SCLERODERMA RELAT / J. Scleroderma Relat. Disord.
Frequency3 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND

Aims and Scopes

The Journal of Scleroderma and Related Disorders focuses on advancing the understanding and management of systemic sclerosis and related conditions. It serves as a platform for innovative research that spans a wide array of clinical, epidemiological, and therapeutic aspects of scleroderma.
  1. Clinical Research on Systemic Sclerosis:
    The journal prioritizes original clinical studies that investigate various manifestations of systemic sclerosis, including its impact on organs such as the lungs, heart, and gastrointestinal tract.
  2. Therapeutic Approaches and Innovations:
    Research articles often explore novel therapeutic strategies and treatment protocols, including the use of biologics, immunosuppressants, and emerging therapies tailored to scleroderma.
  3. Patient-Centered Care and Quality of Life:
    The journal emphasizes studies that assess the quality of life and patient-reported outcomes for individuals with systemic sclerosis, highlighting the importance of psychosocial factors in disease management.
  4. Epidemiological and Public Health Studies:
    There is a consistent focus on epidemiological research that addresses the prevalence, risk factors, and long-term outcomes associated with systemic sclerosis across diverse populations.
  5. Interdisciplinary Approaches:
    The journal encourages interdisciplinary research that brings together insights from various fields such as rheumatology, dermatology, cardiology, and nutrition to provide a holistic understanding of systemic sclerosis.
Recent publications in the Journal of Scleroderma and Related Disorders indicate several emerging themes that reflect the evolving landscape of research in systemic sclerosis. These trends highlight areas of growing interest and potential impact on clinical practice.
  1. Impact of COVID-19 on Systemic Sclerosis:
    An increasing number of studies address the implications of COVID-19 on the management and outcomes of patients with systemic sclerosis, emphasizing the need for adaptive care strategies during the pandemic.
  2. Nutrition and Lifestyle Interventions:
    There is a rising focus on the role of nutrition and lifestyle factors in the management of systemic sclerosis, exploring how these elements can influence disease progression and patient well-being.
  3. Digital Health and Telemedicine:
    Emerging research is examining the use of digital health technologies and telemedicine in the management of systemic sclerosis, particularly in enhancing patient access to care and improving monitoring.
  4. Mental Health and Psychosocial Factors:
    Studies increasingly explore the psychosocial dimensions of living with systemic sclerosis, including the effects of mental health on disease management and quality of life.
  5. Machine Learning and Diagnostic Innovations:
    There is a growing interest in the application of machine learning and other advanced technologies to improve the diagnosis and management of systemic sclerosis, reflecting broader trends in healthcare innovation.

Declining or Waning

While the Journal of Scleroderma and Related Disorders continues to expand its focus, certain themes appear to be declining in prominence. This trend may reflect shifts in research priorities or advancements in understanding that have influenced the scope of inquiry.
  1. Rare and Uncommon Manifestations:
    Research focusing on rare manifestations of systemic sclerosis, such as specific types of skin involvement or rare comorbidities, has decreased. This may indicate a shift towards more prevalent and impactful aspects of the disease.
  2. Historical Perspectives and Case Reports:
    There has been a noticeable reduction in the publication of historical case reports and vignettes, suggesting a possible move towards more data-driven, clinical, and experimental research.
  3. Basic Science Research:
    The journal has seen a waning interest in basic science studies that do not directly translate to clinical implications, possibly due to a growing emphasis on translational research that bridges bench to bedside.

Similar Journals

ACTA NEUROLOGICA SCANDINAVICA

Exploring the Frontiers of Neuroscience
Publisher: WILEYISSN: 0001-6314Frequency: 12 issues/year

ACTA NEUROLOGICA SCANDINAVICA is a prestigious journal published by Wiley that has significantly contributed to the field of neurology and neuroscience since its inception in 1961. With a broad scope encompassing clinical and experimental research, this journal is esteemed for its rigorous peer-review process and high-quality publications. Located in the United Kingdom, it is recognized in the 2023 category quartiles as Q1 in Medicine (miscellaneous) and Q2 in both Neurology and Clinical Neurology, indicating its strong influence and relevance within the medical community. With an H-index demonstrating consistent citation impact, ACTA NEUROLOGICA SCANDINAVICA holds a Scopus rank of #86 out of 400 in Clinical Neurology, reflecting its contribution to advancing current knowledge and practice. Researchers, professionals, and students alike will find in this journal a valuable resource for the latest findings, discussions, and developments in understanding neurological disorders and treatments, furthering educational and clinical endeavors alike.

LANCET NEUROLOGY

Pioneering Research for Clinical Excellence
Publisher: ELSEVIER SCIENCE INCISSN: 1474-4422Frequency: 12 issues/year

The Lancet Neurology is a premier academic journal published by Elsevier Science Inc, specializing in the field of neurology. With a robust impact factor that signifies its authoritative presence, it consistently ranks in the Q1 category for clinical neurology according to the 2023 standards, positioning itself as the leading journal in its domain, ranking #1 out of 400 in Scopus' neurology rankings and placing in the 99th percentile. Since its establishment in 2002, it has provided a vital platform for disseminating innovative research and clinical advances related to neurological disorders. The journal’s precise focus includes cutting-edge studies on neurodegenerative diseases, stroke, epilepsy, and neuroimaging, which are essential for advancing clinical practice and improving patient outcomes. While it does not offer open access, readers can find high-impact research published monthly, making it indispensable for practitioners, researchers, and students eager to stay at the forefront of neurological science.

DERMATOLOGIC CLINICS

Exploring Innovations in Skin Health and Treatment
Publisher: W B SAUNDERS CO-ELSEVIER INCISSN: 0733-8635Frequency: 4 issues/year

DERMATOLOGIC CLINICS is a leading journal in the field of dermatology, published by W B SAUNDERS CO-ELSEVIER INC. Since its inception in 1983, the journal has consistently provided a platform for the dissemination of high-quality research and clinical insights, earning its place in the prestigious Q1 quartile for dermatology in 2023. With a Scopus ranking of #34 out of 142 in its category and a commendable 76th percentile, DERMATOLOGIC CLINICS remains essential reading for clinicians, researchers, and students alike. The journal features comprehensive reviews and original articles that address the latest advancements and challenges in dermatologic diagnostics and treatments. Though it does not offer Open Access, it is widely accessible ensuring a broad readership. With a commitment to advancing the understanding of skin disorders, DERMATOLOGIC CLINICS continues to uphold its legacy of excellence in dermatological scholarship.

Reumatologia Clinica

Exploring breakthroughs in clinical rheumatology.
Publisher: ELSEVIER ESPANA SLUISSN: 1699-258XFrequency: 6 issues/year

Reumatologia Clinica is a distinguished journal dedicated to the field of Rheumatology, published by Elsevier España SLU. With its ISSN of 1699-258X and E-ISSN 1885-1398, the journal aims to disseminate pivotal research findings and clinical studies from 2005 to 2024, spotlighting advancements in the understanding and treatment of rheumatic diseases. Based in Barcelona, Spain, it plays a vital role in the academic community, ranking in the Q3 category for Rheumatology as of 2023, with a Scopus ranking of #44 out of 73, placing it in the 40th percentile. Although it operates under a traditional access model, the journal is committed to academic excellence, providing researchers, healthcare professionals, and students with invaluable insights that drive the field forward. Reumatologia Clinica serves as an essential resource for those looking to deepen their knowledge and contribute to the evolving landscape of rheumatologic research.

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Advancing the Frontiers of Rheumatology Research
Publisher: TAYLOR & FRANCIS LTDISSN: 0300-9742Frequency: 6 issues/year

The Scandinavian Journal of Rheumatology, published by Taylor & Francis Ltd, is a prestigious peer-reviewed journal dedicated to advancing research in the fields of rheumatology, immunology, and related disciplines. With an ISSN of 0300-9742 and an E-ISSN of 1502-7732, this journal has established itself as a vital platform for disseminating significant findings and innovative approaches in the management of rheumatic diseases since its inception in 1959. As a recognized scholarly outlet, it currently resides within the Q2 category for Medicine (miscellaneous) and ranks #39 out of 73 in Rheumatology according to the 2023 Scopus assessments. This reflects the journal's commitment to high-quality research and its relevance in the scientific community. Although it does not provide Open Access options, the journal's rigorous selection process ensures that only the most impactful research reaches its audience, making it a crucial resource for researchers, clinicians, and students engaged in the exploration of rheumatological and immunological challenges. The journal's broad scope encompasses ongoing studies, clinical trials, and reviews that aim to enhance understanding and treatment of rheumatic conditions, promoting collaboration and knowledge-sharing among professionals in the field.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Empowering skin health through groundbreaking research.
Publisher: MOSBY-ELSEVIERISSN: 0190-9622Frequency: 12 issues/year

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, published by Mosby-Elsevier, stands at the forefront of dermatological research and education. With an impressive impact factor and categorized as Q1 in Dermatology, this journal has established itself as a pivotal resource for healthcare professionals and researchers in the field. Since its inception in 1979, it has provided a platform for high-quality peer-reviewed articles, contributing significantly to advancements in dermatological science and practice through 2024. The journal commands an honorable position, ranking #8 out of 142 in the Scopus database's medicine dermatology category, placing it in the 94th percentile among its peers. Readers can access a wealth of cutting-edge studies, case reports, and reviews that address a broad spectrum of topics, from clinical dermatology to emerging therapies. In addition, the journal's commitment to excellence ensures it remains an essential tool for students, clinicians, and researchers dedicated to improving skin health and furthering knowledge in dermatology.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Bridging Research and Practice in Dermatology
Publisher: ADIS INT LTDISSN: 1175-0561Frequency: 6 issues/year

The American Journal of Clinical Dermatology, published by Adis International Ltd, is a leading peer-reviewed journal dedicated to advancing the field of dermatology. With a notable impact factor and a prestigious Q1 rank in both Dermatology and Miscellaneous Medicine categories, this journal stands out as a valuable resource for researchers and clinicians alike, offering cutting-edge insights into clinical practice and innovative treatment strategies. Its comprehensive scope encompasses a broad range of topics within dermatology, addressing both common and rare conditions, with a focus on emerging therapies and technologies. As it converges its publication years from 2000 to 2024, the journal remains an essential platform for disseminating high-quality research to professionals striving to improve patient care and outcomes. With the ISSN 1175-0561 and E-ISSN 1179-1888, the American Journal of Clinical Dermatology facilitates greater accessibility to pivotal findings within the field, making it an indispensable resource for anyone involved in dermatological research and practice.

Therapeutic Advances in Neurological Disorders

Exploring groundbreaking research in neurology.
Publisher: SAGE PUBLICATIONS LTDISSN: 1756-2856Frequency: 1 issue/year

Therapeutic Advances in Neurological Disorders, published by SAGE Publications Ltd, is a leading open access journal dedicated to the advancement of knowledge in the field of neurology. Since its inception in 2008, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for the dissemination of high-quality research that improves the understanding and treatment of neurological disorders. With a commendable impact factor and ranked Q1 in multiple categories, including Neurology and Pharmacology for 2023, it exemplifies excellence in scholarly contributions. The journal's Scope encompasses a wide array of topics, providing insights that are pivotal for clinical practice and pharmacological development. Additionally, with its commitment to open access since 2017, Therapeutic Advances in Neurological Disorders ensures that its research reaches a global audience, fostering collaboration and innovation in neurological science.

International Journal of Rheumatology

Pioneering research for a healthier future.
Publisher: HINDAWI LTDISSN: 1687-9260Frequency: 1 issue/year

The International Journal of Rheumatology, published by HINDAWI LTD, serves as a vital resource for researchers and practitioners in the fields of rheumatology and immunology. Since its inception in 2009 as an Open Access journal, it has aimed to disseminate high-quality, peer-reviewed research to foster advancements in the understanding and treatment of rheumatic diseases. With an ISSN of 1687-9260 and E-ISSN of 1687-9279, the journal has become increasingly relevant, achieving a respectable Q3 ranking in both the Immunology and Rheumatology categories in 2023, and earning a Scopus rank of #27 out of 73 in Medicine Rheumatology. The journal's commitment to excellence is reflected in its wide-ranging scope, addressing current trends and innovations through empirical studies, reviews, and clinical insights. Its global readership, based in the United States and beyond, highlights the journal's importance in shaping the discourse within rheumatological research. As it converges through the years from 2010 to 2024, the International Journal of Rheumatology continues to be a cornerstone for sharing groundbreaking findings and fostering collaboration in the rheumatic disease community.

ANAIS BRASILEIROS DE DERMATOLOGIA

Empowering the Dermatology Community Through Research.
Publisher: ELSEVIER SCIENCE INCISSN: 0365-0596Frequency: 6 issues/year

ANAIS BRASILEIROS DE DERMATOLOGIA is a prestigious academic journal published by Elsevier Science Inc, specializing in the dynamic field of dermatology. With its Open Access model established in 2002, this journal ensures wide dissemination of research findings and facilitates collaboration within the dermatological community. Hailing from Brazil, it provides a platform for innovative research from both local and international contributors, spanning from its inception in 1963 to the current year, 2024. The journal positions itself as a vital resource in the dermatology sphere, currently ranked in the Q3 category for dermatology and holding a notable rank of 71 out of 142 in the Scopus rankings, placing it in the 50th percentile for its field. With a commitment to advancing knowledge and practice in dermatology, ANAIS BRASILEIROS DE DERMATOLOGIA is an essential read for researchers, professionals, and students eager to explore contemporary advancements and clinical practices.